Morphosys CEO says MOR202 drug candidate still promising: newspaper

April 5, 2015 12:07 AM

4 0

FRANKFURT (Reuters) - Morphosys still believes that its MOR202 compound has a good chance of becoming a success after U.S. drugmaker Celgene scrapped cooperation on the drug candidate, the German company's chief executive told a newspaper.

"We are still testing the MOR202 compound in the first clinical phase and still see it as promising," German weekly Welt am Sonntag quoted Simon Moroney as saying in an interview published on Sunday.

Also read: Merck's antiviral drug meets main goal in late-stage trial

Read more

To category page